Extracellular matrix material valve conduit and methods of making thereof

• US 8,696,744 B2
• Filed: 05/24/2012
• Issued: 04/15/2014
• Est. Priority Date: 05/27/2011
• Status: Active Grant

• Current Assignee: Cormatrix Cardiovascular, Inc.
• Original Assignee: Cormatrix Cardiovascular, Inc.
• Inventors: Matheny, Robert G., Gilbert, Christian L., Novick, William
• Primary Examiner(s): IWAMAYE, ANDREW MICHAEL
• Application Number:
  US13/480,324
• Publication Number:
  US 20120310335A1
• Time in Patent Office: 691 Days
• Field of Search: 623/1.24, 623/1.26, 623 147- 148, 623 21- 216
• US Class Current: 623/2.15
• CPC Class Codes: A61F 2/2412 with soft flexible valve members, e.g. tissue valves shaped like natural valves check valves with flexible valve members in general F16K15/14
• CPC Class Codes: A61F 2/2415 Manufacturing methods
• CPC Class Codes: A61L 2/0094 Gaseous substances
• CPC Class Codes: A61L 2430/20 for reconstruction of the heart, e.g. heart valves
• CPC Class Codes: A61L 2430/40 Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
• CPC Class Codes: A61L 27/3633 Extracellular matrix [ECM]
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/3691 characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
• CPC Class Codes: A61L 27/3873 Muscle tissue, e.g. sphincter
• CPC Class Codes: A61L 27/3882 Hollow organs, e.g. bladder, esophagus, urether, uterus
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence

Abstract

Methods for forming extracellular matrix valve conduits are disclosed. Extracellular matrix valve conduits produced using the disclosed methods are also disclosed. Methods of sterilizing and decellularizing extracellular matrix materials are also disclosed.

Claims

1. A method of regenerating a semi-lunar valve to replace a defective semi-lunar valve within a heart of a first subject, the defective semi-lunar valve being attached at an annular region between a ventricle of the heart of the first subject and an artery of the first subject, the method comprising:

providing a sheet of acellular extracellular matrix (ECM) material;

removing the defective semi-lunar valve from the heart of the first subject;

positioning said sheet of ECM material in a folded position, said sheet having a top portion comprising a top edge of said sheet and a bottom portion comprising a bottom edge of said sheet;

wherein, in said folded position, said bottom edge of said sheet is folded toward said top edge of said sheet such that said bottom edge of said sheet is spaced a first distance from said top edge of said sheet;

securing said sheet of ECM material in said folded position, thereby forming a folded ECM valve construct having an upper portion, a lower portion, a first side edge, and a second side edge, said lower portion comprising a first layer and a second layer, said first layer of said lower portion corresponding to said folded bottom portion of said sheet of said ECM material;

attaching said first layer to said second layer only at locations adjacent and along said bottom edge of said sheet, wherein said first and second layers are attached at first and second attachment points, said first attachment point being spaced from said second attachment point by a second distance, wherein a sinus-promoting portion is formed on said ECM valve construct upper portion and a commissure-promoting portion is formed on said ECM valve construct lower portion first layer;

positioning said ECM valve construct in an aligned position, in which said first side edge of said ECM valve construct is in alignment with said second side edge of said ECM valve construct;

with said ECM valve construct in said aligned position, securing said first side edge of said ECM valve construct to said second side edge of said ECM valve construct at a securement location, thereby forming an ECM valve conduit having a lumen and a longitudinal axis, wherein said lower portion of said ECM valve construct corresponds to an inlet portion of said ECM valve conduit, said inlet portion of said ECM valve conduit defining an inlet in fluid communication with said lumen of said ECM valve conduit, wherein said first layer of said lower portion of said ECM valve construct corresponds to an inner layer positioned within said lumen of said ECM valve conduit, wherein said upper portion of said ECM construct corresponds to an outlet portion of said ECM valve conduit, and wherein said second layer of said lower portion of said ECM valve construct cooperates with said upper portion of said ECM valve construct to define an outer wall of said ECM valve conduit, wherein said inner layer of said ECM valve conduit is continuous around its circumference except at said first and second attachment points and said securement location; and

attaching said ECM valve conduit to the annular region of said heart of said first subject and said artery of said first subject, whereby said inlet portion of said ECM valve conduit is positioned proximate said annular region,

wherein, following attachment of said ECM valve conduit to said annular region of said first subject'"'"'s heart and said artery of said first subject,

said commissure-promoting portion of said ECM valve conduit inner layer remodels and fuses with said upper portion of said ECM valve construct, wherein a regenerated valve leaflet of a replacement semi-lunar valve is formed in said ECM valve conduit lumen, and

said sinus-promoting portion remodels and fuses with said ECM valve conduit inner layer of said ECM valve conduit, wherein a regenerated sinus portion of said replacement semi-lunar valve is formed,

said regenerated valve leaflet and said regenerated sinus portion of said ECM valve conduit comprising remodeled cardiovascular tissue.

2. The method of claim 1, wherein said first attachment point and said second attachment point are positioned on a first common plane, said first common plane being perpendicular to said longitudinal axis of said ECM valve conduit.

3. The method of claim 2, wherein said first attachment point is spaced from said first side edge by a third distance, wherein said second attachment point is spaced from said second side edge by a fourth distance, and wherein said third distance and said fourth distance are equal to said second distance by which said first attachment point is spaced from said second attachment point.

4. The method of claim 1, wherein said first layer of said lower portion of said ECM valve construct is further attached to said second layer of said lower portion of said ECM valve construct at a third attachment point intermediate said first side edge and said first attachment point, wherein said first, second, and third attachment points are positioned on a second common plane, said second common plane being perpendicular to said longitudinal axis of said ECM valve conduit, and wherein an additional sinus-promoting portion is formed on said ECM valve construct upper portion and an additional commissure-promoting portion is formed on said lower portion first layer,

and wherein, following attachment of said ECM valve conduit to said annular region of said first subject'"'"'s heart and said first subject'"'"'s artery, said additional sinus-promoting portion remodels and fuses with said inner layer of said ECM valve construct, wherein an additional regenerated sinus portion of said replacement semi-lunar valve is formed, and said additional commissure-promoting portion remodels and fuses with said upper portion of said ECM valve construct, wherein an additional regenerated valve leaflet is formed.

5. The method of claim 4, wherein said third attachment point is spaced from said first attachment point a fifth distance, and wherein said fifth distance equal to said second distance by which said first attachment point is spaced from said second attachment point.

6. The method of claim 4, wherein said first layer of said lower portion of said ECM valve construct is further attached to said second layer of said lower portion of said ECM valve construct at a fourth attachment point intermediate said second side edge and said second attachment point, wherein the first, second, third, and fourth attachment points are positioned on said second common plane.

7. The method of claim 6, wherein said fourth attachment point is spaced from said second attachment point a sixth distance, and wherein said sixth distance equal to said second distance by which said first attachment point is spaced from said second attachment point.

8. The method of claim 1, wherein said sheet of acellular ECM material is decellularized by introducing said ECM material into a reactor pressure vessel, introducing at least a first liquid sterilant into said reactor pressure vessel at a first controlled pressurization rate, pressurizing said reactor pressure vessel at a pressure in the range of 1000-3500 psi, maintaining said ECM material in contact with said first liquid sterilant for a first time period in the range of 10 min. to 24 hours, and depressurizing said reactor pressure vessel at a first depressurizing rate, said first depressurizing rate being greater than 400 psi/min.

9. The method of claim 8, wherein said first liquid sterilant comprises supercritical carbon dioxide.

10. The method of claim 8, wherein said reactor pressure vessel is maintained at a temperature of at least 31.1°

C. during said pressurization of said reactor pressure vessel.

11. The method of claim 1, wherein said ECM material comprises extracellular matrix tissue from a mammalian tissue source, said mammalian tissue source being selected from the group consisting of stomach submucosa, small intestine submucosa, large intestine tissue, bladder tissue, liver tissue, heart tissue, lung tissue, kidney tissue, pancreatic tissue, prostate tissue, fetal tissue, a placenta, a ureter, vein, artery and tissue surrounding growing bone.

12. The method of claim 11, wherein said mammalian tissue source comprises mammalian tissue from a second subject.

13. The method of claim 11, wherein said ECM material includes an additional pharmacological agent.

14. The method of claim 13, wherein said pharmacological agent comprises an anti-inflammatory.

15. The method of claim 13, wherein said pharmacological agent comprises a statin.

16. The method of claim 15, wherein said statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

17. The method of claim 13, wherein said pharmacological agent comprises a growth factor.

18. The method of claim 17, wherein said growth factor is selected from the group consisting of a platelet derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor alpha (TGF-alpha), transforming growth factor beta (TGF-beta), fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), vascular epithelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), platlet derived growth factor (PDGF), and placental growth factor (PLGF).

19. The method of claim 13, wherein said pharmacological agent comprises an anti-arrhythmic agent.